ClinicalTrials.gg
CompletedNCT06399757Updated Oct 5, 2026

A Study to Investigate APL-5125 in Adults With Advanced Solid Tumors

A Phase 1 interventional study of APL-5125 in Colorectal Cancer, Cholangiocarcinoma and Appendiceal Adenocarcinoma, sponsored by Apollo Therapeutics Ltd. Completed at 9 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-05.

Sponsored by Apollo Therapeutics Ltd · Phase 1, Interventional, and Treatment

How we know

Updated Oct 5, 2026Now CompletedPrimary completion moved+6 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
27
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 2,342 studies in Colorectal Neoplasms with a site in United States — 415 open to participants now, 629 under way, 30 of them phase 3. Colorectal Neoplasms · United States.

Enrollment
1,411th of 1,934
27 · median 64
Started
2024
with 123 others
Phase 1
551 of 2,342
99 open now
Registered
2,017th of 2,342
by date

Among the 2,342 studies in Colorectal Neoplasms with a site in United States, this one is the 1,411th largest by enrollment of the 1,934 interventional ones that give a count, is one of 124 that started in 2024, is one of 551 in phase 1, and was the 2,017th registered.

Colorectal Neoplasms

6,556 studies on the registry are indexed under Colorectal Neoplasms; 1,664 are open to participants now.

Browse Colorectal Neoplasms studies →

Open to participants now

415 of the 2,342 studies in Colorectal Neoplasms with a site in United States are open now. Recruiting first, the newest first:

410 more — sign in →

All 415 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 1,179 Colorectal Neoplasms studies recruiting now, 762 (65%) set no upper age limit and 264 (22%) stop at 75 or younger; 48 take children under 18; 123 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 2,342 studies in Colorectal Neoplasms with a site in United States, or all of them as a file.
02

Study summary

This is an open-label, Phase 1/2 study to determine the safety, tolerability, and efficacy of APL-5125 for the treatment of selected locally advanced or metastatic solid tumors with particular focus on Colorectal carcinoma (CRC).

Read the detailed description

The protocol was structured as a Phase 1/2 study with prespecified progression criteria informed by emerging data. Following completion of treatment for the last patient enrolled in Phase 1, it was determined that advancement to the Phase 2 portion of the protocol will not occur.

03

Conditions studied

  • Colorectal Cancer
  • Cholangiocarcinoma
  • Appendiceal Adenocarcinoma
  • Pancreatic Adenocarcinoma
  • Gastric Adenocarcinoma
  • Endometrial Adenocarcinoma
  • Triple Negative Breast Cancer
  • Ovarian Cancer
  • Prostate Cancer
04

Who can participate

The criteria were revised on the registry on Oct 5, 2026. See what changed

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • 18 years or older
  • Phase 1: confirmed locally advanced, inoperable, or tumor; Colorectal carcinoma, Cholangiocarcinoma, Appendiceal adenocarcinoma.
  • No available standard of care therapy or participant is ineligible for standard of care therapy, except in CRC tumor type in which participant must have previously received all the following therapeutic agents:

    • fluoropyrimidine-, oxaliplatin- and irinotecan-based chemotherapy
    • an anti-VEGF therapy
    • if wt-RAS (wt-KRAS and wt-NRAS), an anti-EGFR therapy
  • (ECOG) ≤1
  • Body Weight ≥40 kg.
  • Female participants of must have negative serum pregnancy test at screening; must not plan to become pregnant or have ova harvested or breastfeed while on study; must be willing to use specific or avoid intercourse
  • Male participants must be willing to use specific contraception and not plan to impregnate a female partner or donate sperm while on study
  • Participant must be willing and able to provide written and to comply with the requirements of the trial

Exclusion criteria

Exclusion Criteria:

  • Certain medical conditions such as: active , carcinomatous meningitis, unstable angina pectoris, myocardial infarction or ventricular arrhythmias, symptomatic congestive heart failure, uncontrolled active infection, history of significant hemorrhage within 4 weeks of the first dose date, intestinal disease or major gastric surgery, arterial thrombosis within 6 months of screening
  • Certain prior therapies such as: anti-cancer treatment within 2 weeks of Cycle 1 Day 1, prior radiotherapy within 14 days before screening, active anti-coagulation therapy, over the counter or prescription medications within 14 days or 5 half-lives prior to cycle 1 day 1, herbal medicines and supplements within 14 days
  • Major surgery within 1 month of screening
  • \< 9.0 g/dL
  • \< 1.5 x 10\^9/L
  • count \< 100 x 10\^9/L
  • Hepatic function:

    1. and/or alanine aminotransferase (ALT) >3 × (ULN) (>5 x ULN for subjects with liver )
    2. Total >1.5 × ULN (except participants with Gilbert's syndrome).
    3. Albumin \< 3 g/dL
  • Calculated or measured of \<60 mL/minute calculated using the formula of Cockcroft and Gault ([140 - Age] × Mass [kg] / [72 × serum creatinine mg/dL]). Multiply result by 0.85 if female.
  • Fridericia's interval (QTcF) >470 msec or a family history of Long QT Syndrome.
  • Cardiac function: Echocardiogram (or ) showing Left Ventricular Ejection Fraction (LVEF) \<45% at rest
  • Infectious diseases: positive for (unless controlled with active retroviral therapy), and
Terms in these criteria, in plain language(20)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
27 participants (actual)

Study arms

  • Experimental
    Phase 1: Dose Escalation

    Dose escalation with increasing dose levels of APL-5125 to identify Recommended Phase 2 Dose. Possibility to expand into select populations

    Drug: APL-5125

Interventions

  • DrugAPL-5125

    APL-5125 is an oral drug (capsule) taken daily in 28-day cycles

06

What researchers measure

Primary outcomes

  1. Incidence of Treatment Emergent Adverse Events [Safety]

    Evaluation of safety parameters including treatment emergent adverse events as detected by hematology, chemistry, coagulation safety labs, physical exams, vital signs, electrocardiogram results.

    Time frame: Through study completion, approximately one year

  2. Incidence of dose limiting toxicities [Tolerability] (Phase 1)

    Evaluation of tolerability parameters including dose limiting toxicities as detected by hematology, chemistry, coagulation safety labs, physical exams, vital signs and electrocardiogram results

    Time frame: Cycle 1 Day 1 to Cycle 2 Day 1 (a cycle is 28 days)

  3. Determine Recommended Phase 2 Dose (RP2D) levels of APL-5125 in participants with selected advanced solid tumors (Phase 1)

    Time frame: Approximately one year

Secondary outcomes

  1. Assess the preliminary anti-tumor activity of APL-5125 in colorectal carcinoma patients (Phase 1)

    Response is assessed per RECIST version 1.1 criteria

    Time frame: Response is assessed every 8 weeks; after one year of treatment, response is assessed every 12 weeks. (Assessed for up to 2 years.)

  2. Assess the pharmacokinetics (PK) of APL-5125 (Phase 1)

    Evaluate PK parameters: oral clearance

    Time frame: On days 1, 2, 4, 8, 15 of cycle 1, and on day 1 of cycle 2 and cycle 3 (a cycle is 28 days).

  3. Assess the pharmacokinetics (PK) of APL-5125 (Phase 1)

    Evaluate PK parameters: volume of distribution

    Time frame: On days 1, 2 ,4, 8, 15 of cycle 1, and on day 1 of cycle 2 and cycle 3 (a cycle is 28 days).

  4. Evaluate biomarker(s) in the tumor

    Assessment of biomarker(s) in pre- and post-treatment tumor tissue

    Time frame: Through study completion, approximately one year

07

Study locations

9 sites
  • City of Hope
    Duarte, California 91010, United States
  • City of Hope Orange County Lennar Foundation Cancer Center
    Irvine, California 92618, United States
  • Florida Cancer Specialists & Research Institute
    Sarasota, Florida 34232, United States
  • University of Michigan
    Ann Arbor, Michigan 48109, United States
  • Duke Cancer Institute
    Durham, North Carolina 27710, United States
  • Carolina BioOncology Institute
    Huntersville, North Carolina 28078, United States
  • Medical University of South Carolina
    Charleston, South Carolina 29425, United States
  • Mary Crowley Cancer Research
    Dallas, Texas 75251, United States
  • NEXT Oncology- San Antonio
    San Antonio, Texas 78229, United States
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jun 2024 to primary completion in Jul 2026, 24 months.

Of 269 industry-sponsored phase 1 interventional studies under Colorectal Neoplasms, half reached primary completion within 47 months of starting (the median), counting those still running; a quarter within 31 and three quarters within 66. This study's 24 months is below that.

Counting every sponsor, half of 435 studies reached it within 48 months; a quarter within 31 and three quarters within 70.

Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 5, 2026: primary completion Apr 2027 → Jul 2026 and completion May 2027 → Jul 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
May 1, 2024
First posted
May 6, 2024
StartActual
Jun 18, 2024
Primary completionActual
Jul 8, 2026was Apr 2027
CompletionActual
Jul 8, 2026was May 2027
Last update
Oct 5, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Active, not recruiting→Completed
changed Oct 5, 2026
Primary completion
Apr 2027→Jul 8, 2026 (actual)
Oct 5, 2026
Study completion
May 2027→Jul 8, 2026 (actual)
Oct 5, 2026
Enrollment
100 (estimated)→27 (actual)
Oct 5, 2026
Eligibility
2 inclusion criteria removed
What changed in the criteria
Inclusion criteria
  • RemovedFor Phase 1 sub-studies: Colorectal carcinoma, Cholangiocarcinoma, Appendiceal adenocarcinoma, Pancreatic Adenocarcinoma, Gastric Adenocarcinoma, Endometrial Adenocarcinoma, Triple Negative Breast Cancer, Ovarian Cancer, Prostate Cancer
  • RemovedPhase 2: Colorectal carcinoma
Oct 5, 2026
Interventions
Arms removed: Phase 2: Dose Expansion/Optimization
Oct 5, 2026
Primary outcomes
1 removed
What changed in the outcomes
  • RemovedAssess the anti-tumor activity of APL-5125 in patients with Colorectal carcinoma (Phase 2)Time frame: Response is assessed every 8 weeks; after one year of treatment, response is assessed every 12 weeks. (Assessed for up to 2 years.)
Oct 5, 2026
Secondary outcomes
4 removed
What changed in the outcomes
  • RemovedFurther assess the anti-tumor activity of APL-5125 (Phase 2)Time frame: Response is assessed every 8 weeks; after one year of treatment, response is assessed every 12 weeks. (Assessed for up to 2 years.)
  • RemovedIncidence of treatment emergent adverse events [Further Safety] (Phase 2)Time frame: Through study completion (approximately 2 years)
  • RemovedFurther assess the PK of APL-5125 (Phase 2)Time frame: On days 1 and 8 of cycle 1, and on day 1 of cycle 2 and cycle 3 (a cycle is 28 days).
  • RemovedFurther assess the PK of APL-5125 (Phase 2)Time frame: On days 1 and 8 of cycle 1, and on day 1 of cycle 2 and cycle 3 (a cycle is 28 days).
Oct 5, 2026
Design
Removed Phase 2
Oct 5, 2026
Show all 1 update
  1. Oct 5, 2026
    Active, not recruiting→Completed
    Primary completion Apr 2027→Jul 8, 2026 (now actual)
    Study completion May 2027→Jul 8, 2026 (now actual)
    Enrollment 100 (estimated)→27 (actual)
    Eligibility 2 inclusion criteria removed
    What changed in the criteria
    Inclusion criteria
    • RemovedFor Phase 1 sub-studies: Colorectal carcinoma, Cholangiocarcinoma, Appendiceal adenocarcinoma, Pancreatic Adenocarcinoma, Gastric Adenocarcinoma, Endometrial Adenocarcinoma, Triple Negative Breast Cancer, Ovarian Cancer, Prostate Cancer
    • RemovedPhase 2: Colorectal carcinoma
    Primary outcomes 1 removed
    What changed in the outcomes
    • RemovedAssess the anti-tumor activity of APL-5125 in patients with Colorectal carcinoma (Phase 2)Time frame: Response is assessed every 8 weeks; after one year of treatment, response is assessed every 12 weeks. (Assessed for up to 2 years.)
    Secondary outcomes 4 removed
    What changed in the outcomes
    • RemovedFurther assess the anti-tumor activity of APL-5125 (Phase 2)Time frame: Response is assessed every 8 weeks; after one year of treatment, response is assessed every 12 weeks. (Assessed for up to 2 years.)
    • RemovedIncidence of treatment emergent adverse events [Further Safety] (Phase 2)Time frame: Through study completion (approximately 2 years)
    • RemovedFurther assess the PK of APL-5125 (Phase 2)Time frame: On days 1 and 8 of cycle 1, and on day 1 of cycle 2 and cycle 3 (a cycle is 28 days).
    • RemovedFurther assess the PK of APL-5125 (Phase 2)Time frame: On days 1 and 8 of cycle 1, and on day 1 of cycle 2 and cycle 3 (a cycle is 28 days).
    Interventions Arms removed: Phase 2: Dose Expansion/Optimization
    Design Removed Phase 2
    + 2 other changes: verification date and description

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT06399757
Lead sponsor
Apollo Therapeutics Ltd
Responsible party
Sponsor
First posted
May 6, 2024
Start date
Jun 18, 2024
Primary completion
Jul 8, 2026
Completion
Jul 8, 2026
Last update
Oct 5, 2026

Study contacts

Sanjay Aggarwal, MD
study chair · Apollo Therapeutics Ltd

Oversight

FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion